IP Verse

Teva competitive analysis

Latest oppositions filed by Teva

Explore patent oppositions filed by Teva against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Jul 2, 2026
Patent NumberTitleApplicantOpposition Date
EP3689365
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKApr 19, 2026
EP4374918
Methods Of Treating Fabry Patients Having Renal ImpairmentAMICUS THERAPEUTICSApr 15, 2026
EP3362049
Stabilizing Camptothecin Pharmaceutical CompositionsIPSEN BIOPHARMApr 7, 2026
EP3700529
New Combination Of Active Agents For The Treatment Of Progressive Fibrosing Interstitial Lung Diseases (Pf-Ild)BOEHRINGER INGELHEIMApr 2, 2026
EP4284410
Compositions And Methods For The Treatment Of Graft Versus Host DiseaseVECTIVBIOApr 2, 2026
EP4426307
New Oral Pharmaceutical Composition And Dose Regimen For The Therapy Of Progressive Fibrosing Interstitial Lung DiseasesBOEHRINGER INGELHEIMApr 2, 2026
EP3793587
Starting Dose Of Pth ConjugatesASCENDIS PHARMA BONE DISEASESApr 1, 2026
EP4316598
Pharmaceutical Composition Containing Poorly-Soluble Basic MedicineCHUGAI SEIYAKU KABUSHIKI KAISHAMar 18, 2026
EP3908276
Methods Of Treating Conditions Related To The S1P1 ReceptorARENA PHARMACEUTICALSMar 10, 2026
EP3481467
Method For Reducing An Amount Of Subvisible Particles In A Pharmaceutical CompositionBECTON DICKINSON FRANCEDec 5, 2025

Latest patents of Teva opposed by its competitors

Explore Teva's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jul 2, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP3798224
Mar 19, 2025Solid State Forms Of Ixazomib Citrate1
EP4097091
Sep 18, 2024Solid State Forms Of Mavacamten And Process For Preparation Thereof3
EP3554581
Mar 13, 2024Medical Injection Device Packaging2
EP3497104
Oct 6, 2021Solid State Forms Of Lumateperone Ditosylate Salt1
EP3344607
Nov 6, 2019Solid State Forms Of Selexipag2
EP2897588
Jul 17, 2019An Inhalable Medicament1
EP3143998
May 22, 2019An Inhalable Medicament Comprising Tiotropium2
EP3045182
Mar 7, 2018Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide And Methods Using Same2
EP2800567
Sep 27, 2017An Inhaler Comprising A Tiotropium-Containing-Composition2
EP3050556
Mar 22, 2017Process For Manufacturing A Pharmaceutical Preparation Containing Glatiramer Acetate2

Latest PTAB cases involving Teva

Discover the latest PTAB cases involving Teva, highlighting their recent legal challenges and patent disputes.

Last updated on: Jul 1, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Teva

IPR2022-01513Sep 9, 2022TEVA PHARMACEUTICALSBAYER PHARMATerminated-Adverse Judgment
IPR2022-00796Apr 11, 2022ELI LILLYTEVAFinal Written Decision
IPR2022-00796Apr 11, 2022ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
IPR2022-00738Mar 23, 2022ELI LILLYTEVAFinal Written Decision
IPR2022-00738Mar 23, 2022ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
IPR2022-00739Mar 23, 2022ELI LILLYTEVAFinal Written Decision
IPR2022-00739Mar 23, 2022ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
IPR2020-01045Jun 10, 2020TEVA PHARMACEUTICALSMERCK SHARP & DOHMETerminated-Settled
PGR2019-00048May 7, 2019TEVA PHARMACEUTICALSCORCEPT THERAPEUTICSFinal Written Decision
IPR2018-01711Oct 1, 2018ELI LILLYTEVAFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Teva with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Jul 2, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
TEVA2 - - 12
ELI LILLY4341715
NEURODERM - 11 -
NOVARTIS6520 - 21